Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose co-transporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial
Lam CSP, Ramasundarahettige C, Branch KRH, et al.
Circulation. Pub. online 14 November 2021.
Leggi